Mindbreeze is named “a Leader” in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment
5.12.2024 19:14:00 CET | Business Wire | Press release
Mindbreeze, a global leader in AI-powered enterprise intelligence, is named a Leader in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment (doc #US51541224, December 2024).
Mindbreeze InSpire is transforming the future of enterprise intelligence, revolutionizing how organizations unlock the power of their information. Powered by advanced AI agents, it seamlessly integrates and analyzes structured and unstructured data from diverse systems, turning complexity into clarity. By creating dynamic insight journeys, Mindbreeze InSpire delivers hyper-relevant, context-aware insights tailored to employees’ unique roles and needs—enabling smarter decisions at every level. Beyond streamlining business process transformation, it empowers organizations to fully realize the value of their information ecosystems, driving innovation and securing a competitive edge in today’s fast-paced, data-driven world.
Therefore, “Consider Mindbreeze if you are a large enterprise customer looking for a knowledge management solution that can cater to business areas such as customer service, finance, legal, and HR. Pre-built search applications tailored to specific departments can enhance knowledge creation and search capabilities, while supporting broader business process transformations.”
“We are honored to be recognized as a 'Leader' in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment,” says Daniel Fallmann, founder and CEO of Mindbreeze. “Our focus on delivering tailored insight journeys and flexible deployment options empowers businesses to unlock the true potential of generative AI use cases, seamlessly integrating them into daily workflows across the enterprise. This capability is key to driving business process transformation and automation, putting our customers in a winning position to thrive in a competitive landscape. We are proud of the pivotal role of our solutions in achieving these outcomes.”
Over 2,700 of the world's largest companies across a variety of industries rely on Mindbreeze to manage their information more efficiently and intelligently.
About the IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
About Mindbreeze
Mindbreeze is a global leader in AI-powered enterprise intelligence, with locations in Europe and the US and a robust partner network worldwide. Mindbreeze InSpire redefines how organizations access and utilize information. Powered by advanced AI, it transforms complex data into actionable insights, seamlessly connecting and analyzing information across systems.
Unlike traditional solutions, our AI agents deliver hyper-relevant, context-aware insights tailored to unique business needs, enabling smarter, faster decision-making. With unmatched integration capabilities, enterprise-grade data security, and automation at its core, Mindbreeze InSpire maximizes the value of your information ecosystem while driving business innovation.
Trusted by industry leaders and recognized for our cutting-edge technology, Mindbreeze leads the way in unlocking new dimensions of enterprise intelligence.
Learn more at www.mindbreeze.com or follow us on LinkedIn and X @Mindbreeze.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205572409/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom